Aplastic Anaemia, Chemotherapy Induced Thrombocytopenia, Immune Thrombocytopenia, Myelodysplasia
Conditions
Keywords
ITP, Thrombocytopenia, mean platelet mass, mean platelet component
Brief summary
To utilise extended platelet parameters in order to individuate Immune Thrombocytopenia (ITP) from hypo-proliferative causes of thrombocytopenia. To develop the clinical potential of the extended platelet parameters as they pertain to distinguishing different causes of thrombocytopenia from one another. To test the hypothesis that mean platelet component (MPC) and mean platelet mass (MPM) might distinguish between thrombocytopenia related to bone marrow dysfunction and immune mediated destruction of platelets.
Detailed description
Patient to be registered at the Haematology-Oncology department Mount Sinai Roosevelt Hospital. Inclusion criteria are as follows: All individuals age 18yrs and above capable of rendering consent Known ITP confirmed by response to IVIG, glucocorticoids, or WinRho and exclusion of all other possible causes of thrombocytopenia Confirmed aplastic anemia \[as assessed through bone marrow trephine biopsy\]. Chemotherapy-induced thrombocytopenia assessed at time of predicted nadir.
Interventions
OTHERImmune Thrombocytopenics
Full blood count with extended platelet parameters
OTHERHypo-proliferative thrombocytopenics
Full blood count with extended platelet parameters
OTHERControl Population
Full blood count with extended platelet parameters
Sponsors
Beth Israel Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* All individuals age 18yrs and above capable of rendering consent * Known ITP confirmed by response to intravenous immune globulin (IVIG), glucocorticoids, or winRho and exclusion of all other possible causes of thrombocytopenia * Confirmed aplastic anemia \[as assessed through bone marrow trephine biopsy\] * Chemotherapy induced thrombocytopenia assessed at time of predicted nadir.
Exclusion criteria
* Suspected multifactorial thrombocytopenias and thrombocytopenia due to hypersplenism * Chronic active hepatitis * Those infected with HIV * Patients receiving concomitant radiotherapy * Gravid females * Congenital thrombocytopenias
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Increased platelet density | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| mean platelet mass | 12 months |
Other
| Measure | Time frame |
|---|---|
| Platelet mass distribution width | 12 Months |
Countries
United States
Outcome results
None listed